# Ajuvant Chemotherapy and Immunotherapy in Patients With Esophageal, Esophageal- Gastric Junction Cancer

> **NCT04688801** · NA · RECRUITING · sponsor: **The Second Hospital of Shandong University** · enrollment: 200 (estimated)

## Conditions studied

- Esophageal Cancer
- Gastroesophageal Cancer
- Immunotherapy
- Adjuvant

## Interventions

- **DRUG:** Chemotherapy Drugs, Cancer
- **DRUG:** Immunotherapy

## Key facts

- **NCT ID:** NCT04688801
- **Lead sponsor:** The Second Hospital of Shandong University
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2020-07-01
- **Primary completion:** 2023-12-31
- **Final completion:** 2027-12-31
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2022-11-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04688801

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04688801, "Ajuvant Chemotherapy and Immunotherapy in Patients With Esophageal, Esophageal- Gastric Junction Cancer". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT04688801. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*